Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application

Lilly had previously announced that patients with obesity but not diabetes lost an average of 28.3% of their weight in an 80-week trial of retatrutide. Positive results were also seen in Phase 3 studies of the drug's impact on knee osteoarthritis pain and obstructive sleep apnea.

"Across five positive Phase 3 studies, retatrutide has shown powerful efficacy, and we believe it could be an important future tool in the management of cardiometabolic health," Lilly Executive Vice President Kenneth Custer said in a statement.

Lilly said it plans to submit a biologics license application for retatrutide to the FDA in the first quarter of next year. The company also said full results of the latest trials will be published in medical journals at a later date.